Leland Gershell News Today

/PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — today...

Investor interest in newly-issued biotech stocks has been moribund for years, but the sector’s first IPO of 2024, CG Oncology, suggests that investors might...

Operator: Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that todays conference is being recorded.

Approval Likely in U.S., EU for New Drug for Prader-Willi

After a shaky August for the markets, we have now entered the year’s final third and the bad news is that, going by the history books, September represents the market’s worst month of the year. The good news, however, is that according to Oppenheimer’s head of technical analysis, Ari Wald, any anticipated lull will be short-lived. “The key takeaway in our work is that, whether or not the advance is resuming imminently, it should only be a matter of time,” Wald ...

Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript September 5, 2023 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $2.16, expectations were $-2.68. Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a […]

Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating 

Operator: Good afternoon, and welcome to Lumos Pharmas Q2 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Operator: Good afternoon and welcome to the Trevi Therapeutics’ Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

It’s been clear for a while now that the stock market is on an upward trajectory, buoyed by a resilient economy and retreating high inflation. The good news, according to John Stoltzfus, Chief Investment Strategist at Oppenheimer, is that the chances of the bull market continuing are more likely than the bears grabbing hold of the narrative once again. “Our appraisal of the market landscape at this time suggests that opportunity outweighs risk as current monetary policy generates a...